CH117071A - Colloidal solution intended to serve as a carrier vehicle for radioactive substances and in particular for radium emanations. - Google Patents
Colloidal solution intended to serve as a carrier vehicle for radioactive substances and in particular for radium emanations.Info
- Publication number
- CH117071A CH117071A CH117071DA CH117071A CH 117071 A CH117071 A CH 117071A CH 117071D A CH117071D A CH 117071DA CH 117071 A CH117071 A CH 117071A
- Authority
- CH
- Switzerland
- Prior art keywords
- solution
- alkaline earth
- alkali
- hydrate
- earth metal
- Prior art date
Links
- 239000000941 radioactive substance Substances 0.000 title claims description 6
- 229910052705 radium Inorganic materials 0.000 title claims description 4
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 title claims description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 11
- 239000000084 colloidal system Substances 0.000 claims description 11
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 108010010803 Gelatin Proteins 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 239000008273 gelatin Substances 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 150000001340 alkali metals Chemical class 0.000 claims description 3
- 229960002684 aminocaproic acid Drugs 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims 5
- JBBURJFZIMRPCZ-XRIGFGBMSA-N (2s)-2,6-diaminohexanoic acid;hydron;dichloride Chemical compound Cl.Cl.NCCCC[C@H](N)C(O)=O JBBURJFZIMRPCZ-XRIGFGBMSA-N 0.000 claims 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 claims 2
- 235000011941 Tilia x europaea Nutrition 0.000 claims 2
- 239000004571 lime Substances 0.000 claims 2
- 239000000243 solution Substances 0.000 description 14
- 230000002285 radioactive effect Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 2
- -1 alkaline earth metal salt Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 206010048909 Boredom Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000679125 Thoron Species 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical class [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- DCSRPHQBFSYJNN-UHFFFAOYSA-L disodium 4-[(2-arsonophenyl)diazenyl]-3-hydroxynaphthalene-2,7-disulfonate Chemical compound [Na+].[Na+].Oc1c(N=Nc2ccccc2[As](O)(O)=O)c2ccc(cc2cc1S([O-])(=O)=O)S([O-])(=O)=O DCSRPHQBFSYJNN-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 229910052704 radon Inorganic materials 0.000 description 1
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 1
- SYUHGPGVQRZVTB-OIOBTWANSA-N radon-219 atom Chemical compound [219Rn] SYUHGPGVQRZVTB-OIOBTWANSA-N 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
- A61K51/1289—Devices or containers for impregnation, for emanation, e.g. bottles or jars for radioactive water for use in radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Solution colloïdale destinée à servir de véhicule-support à des substances radioactives et en particulier à des émanations de radium. La présente invention a pour objet une solution colloïdale destinée à servir de véhi- cule-support à des substances radioactives et tout particulièrement à des émanations de radium.
On sait en effet que les corps radioactifs ont un champ d'application toujours plus étendu, parmi eux particulièrement les éma nations-. radon, thoron et actinon.
Or, celles-ci sont assez difficilement ma niables parce que très peu solubles dans les solvants ordinaires.
Ces corps ont des emplois très divers. La médecine leur demande la plus forte contribution, qu'il s'agisse soit de médica ments radioactifs sous forme d'injections, soit d'eaux radioactives médicinales (traite ment des néoplasmes; méthode du docteur Kotzareff).
En outre, on recherche activement le rôle de ces émanations sur la culture des plantes, sur les engrais tout spécialement. Parmi les solvants de ces émanations ou de ces corps radioactifs, on a utilisé les col loïdes organiques et minéraux; cependant leur emploi en médecine peut être très dangereux et les autres applications des corps radioactifs ne demandent pas d'emploi de ces substances particulièrement chères. De plus, le coefficient de solubilité de l'éma nation dans ces corps est assez faible.
Ils ne sont pas d'une préparation facile. La solution colloïdale selon l'invention obvie à ces graves inconvénients et permet d'éviter l'ennui de manipulations excessive ment délicates.
Cette solution, en effet, supporte de hautes doses d'émanations dans un volume de liquide très restreint. A l'aide de cette solution on peut préparer des produits dont l'emploi en thérapeutique, par exemple, lorsque cette solution est chargée d'émana tions, est sans danger et dont l'application dans les autres domaines est aisée.
Cette solution est obtenue à l'aide des ingrédients suivants De l'eau,- comme solvant, un sel halogéné d'un métal alcalin ou alcalino-terreux, un colloïde organique, un acide aminé et un hydrate d'un métal alcalin ou alcalino- terreux.
Elle peut être préparée par exemple comme suit: On dissout le colloïde organique dans une solution de sel halogéné de métal alca lin ou alcalino-terreux dans l'eau distillée.
Le colloïde peut être dissous à des con centrations différentes en rapport avec la charge d'émanations ou de substances radio actives -plus ou moins considérables que de vra supporter la solution; plus la concen tration en forces radioactives doit être éle vée, plus la concentration du colloïde est élevée.
La suspension colloïdale se fait en chauffant le colloïde dans la solution saline, en prenant garde que les concentrations sa lines soient conservées. Cela s'obtient soit en chauffant sous réfrigérant (moyen cou rant) soit en chauffant à l'autoclave le colloïde dans la solution.
La solution faite et refroidie est en gé néral d'un PI, d'environ 6 à 6,5 soit légère ment acide: elle est additionnée avec toutes les précautions d'asepsie, pour en respecter la stérilité, de sel d'acide aminé.
Le mélange est fortement acide. On mesure son Ph. On ramène le liquide à l'alcalinité par adjonction d'un hydrate de métal alcalino-terreux jusqu'à ce que le mé lange final ait un Ph de 7,4 à 8. La so lution est alors prête à l'usage. Elle supporte toutes les charges radioactives employées couramment.
Comme sel halogéné on emploie de pré férence le chlorure de sodium dans la pro portion voulue pour former une solution physiologique (8,35 %o NaCI).
Le colloïde organique peut être la géla tine telle qu'on la trouve dans le commerce, en feuilles blanches, à la concentration de 2 %o à 2%. Son but est de fixer la subs- tance radioactive.
L'acide aminé peut être le bichloi-hydrate de lysine en poudre sèche (acide di-amino caproïque) à la concentration de 1 pour mille de solution gélatinée. L'hydrate alcalino-terreux peut être l'eau de chaux saturée [Ca (OH) 2] stérile, ajoutée en quantité suffisante pour amener le Pli du mélange de 7,4 à 8.
Colloidal solution intended to serve as a carrier vehicle for radioactive substances and in particular for radium emanations. The present invention relates to a colloidal solution intended to serve as a carrier vehicle for radioactive substances and more particularly for radium fumes.
We know, in fact, that radioactive bodies have an ever-expanding field of application, among them particularly ema nations. radon, thoron and actinon.
However, these are quite difficult to manage because they are very poorly soluble in ordinary solvents.
These bodies have a wide variety of jobs. Medicine demands the greatest contribution from them, whether it be for radioactive drugs in the form of injections or for medicinal radioactive water (treatment of neoplasms; method of Dr Kotzareff).
In addition, the role of these emanations on the cultivation of plants, especially on fertilizers, is being actively researched. Among the solvents of these emanations or of these radioactive bodies, organic and mineral necks have been used; however, their use in medicine can be very dangerous and other applications of radioactive bodies do not require the use of these particularly expensive substances. In addition, the solubility coefficient of the emanation in these bodies is quite low.
They are not easy to prepare. The colloidal solution according to the invention obviates these serious drawbacks and makes it possible to avoid the boredom of excessively delicate handling.
This solution, in fact, supports high doses of emanations in a very small volume of liquid. Using this solution, products can be prepared whose use in therapy, for example, when this solution is loaded with emanations, is harmless and whose application in other fields is easy.
This solution is obtained using the following ingredients Water, - as solvent, a halogenated salt of an alkali metal or alkaline earth metal, an organic colloid, an amino acid and a hydrate of an alkali metal or alkaline - earthy.
It can be prepared for example as follows: The organic colloid is dissolved in a solution of halogenated alkaline or alkaline earth metal salt in distilled water.
The colloid can be dissolved at different concentrations in relation to the charge of emanations or radioactive substances - more or less considerable than actually supporting the solution; the higher the concentration of radioactive forces, the higher the concentration of the colloid.
The colloidal suspension is made by heating the colloid in the saline solution, taking care that the sa lines concentrations are maintained. This is obtained either by heating under refrigerant (medium current) or by autoclaving the colloid in the solution.
The solution made and cooled generally has a PI, of about 6 to 6.5, or slightly acidic: it is added with all the precautions of asepsis, to respect its sterility, of amino acid salt. .
The mixture is strongly acidic. Its Ph is measured. The liquid is brought back to alkalinity by adding an alkaline earth metal hydrate until the final mixture has a Ph of 7.4 to 8. The solution is then ready for use. use. It supports all commonly used radioactive charges.
As the halogenated salt, sodium chloride is preferably used in the desired proportion to form a physiological solution (8.35% o NaCl).
The organic colloid can be gelatin as found in commerce, in white sheets, at a concentration of 2% to 2%. Its purpose is to fix the radioactive substance.
The amino acid may be dry powdered lysine bichloihydrate (di-amino caproic acid) at a concentration of 1 per thousand gelatin solution. The alkaline earth hydrate can be sterile [Ca (OH) 2] saturated lime water, added in sufficient quantity to bring the Pli of the mixture from 7.4 to 8.
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH117071T | 1925-09-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
CH117071A true CH117071A (en) | 1926-10-16 |
Family
ID=4376099
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CH117071D CH117071A (en) | 1925-09-07 | 1925-09-07 | Colloidal solution intended to serve as a carrier vehicle for radioactive substances and in particular for radium emanations. |
Country Status (1)
Country | Link |
---|---|
CH (1) | CH117071A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2808011A (en) * | 1952-08-21 | 1957-10-01 | Miller Hofft Inc | Furnace for burning semi-liquid fuels |
-
1925
- 1925-09-07 CH CH117071D patent/CH117071A/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2808011A (en) * | 1952-08-21 | 1957-10-01 | Miller Hofft Inc | Furnace for burning semi-liquid fuels |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6926913B2 (en) | Composition containing molecular iodine | |
CH616080A5 (en) | ||
EP0316993B1 (en) | Pharmaceutical compositions containing a derivative of 3-hydroxy-butanoic acid chosen among oligomers of this acid and among esters of this acid or of these oligomers with 1,3-butane-diol | |
FR2688405A1 (en) | Process for preparing a stable, controlled-release medicinal solution for oral administration based on a beta-blocker, and pharmaceutical composition based on a beta-blocker. | |
JP5297815B2 (en) | Pharmaceutical composition | |
DE1668930C3 (en) | New alkylaminopropanols and their salts with acids, processes for their preparation, as well as therapeutic agents | |
CA2119270A1 (en) | Sparfloxacine salts and solutions containing them | |
CH117071A (en) | Colloidal solution intended to serve as a carrier vehicle for radioactive substances and in particular for radium emanations. | |
DE3853493T2 (en) | Superoxide dismutase derivatives, process for their preparation and their use as medicines. | |
CH636766A5 (en) | SOLUTION FOR INFUSION FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY AND A METHOD OF PREPARATION THEREOF. | |
DE60317303T2 (en) | Hemoglobin conjugates | |
JP2004315470A (en) | Pharmaceutical preparation containing sodium iodide | |
BE336476A (en) | ||
DE2136067A1 (en) | Fluorinated amino acids | |
CN115282126B (en) | A mannose-modified plumbagin nanostructure lipid carrier and its preparation method and application | |
FR2468366A1 (en) | Acetazolamide or methazolamide anti:glaucoma compsn. - is buffered at pH 6-9, using an aminoacid, esp. l-lysine, for local administration e.g. as an eyewash | |
EP0621779B1 (en) | Indomethacin lysinate for therapeutic use in ophthalmology | |
JP3000490B2 (en) | Anti-tineamyces agent | |
JP2010265209A (en) | Iodine liquid preparation | |
FR2581311A1 (en) | Pharmaceutical compositions for the treatment of colites and colopathies, based on thyme oil and cade essential oil. | |
GB1569380A (en) | Pharmaceutical compositions comprising substituted phenyl-amino-alcohol and process for preparing these compositions | |
SU1824123A1 (en) | Method of anesthetic treatment of fish | |
AT129764B (en) | Process for the preparation of new water-soluble compounds of 2-phenylquinoline-4-carboxylic acid and its derivatives. | |
FR2518405A1 (en) | MIXTURE OF SODIUM CROMOGLYCATE AND XYLOMETAZOLINE AND PROCESS FOR PREPARING THE SAME | |
RU2063227C1 (en) | Medicinal agent for cardiovascular disease treatment and method of its preparing |